Compare DARE & MDBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DARE | MDBH |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6M | 18.3M |
| IPO Year | 2014 | 2022 |
| Metric | DARE | MDBH |
|---|---|---|
| Price | $0.67 | $1.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.33 | N/A |
| AVG Volume (30 Days) | ★ 107.4K | 4.5K |
| Earning Date | 11-16-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,807,885.00 | N/A |
| Revenue This Year | $116.54 | N/A |
| Revenue Next Year | $201.20 | N/A |
| P/E Ratio | ★ N/A | $4.06 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.63 | $1.31 |
| 52 Week High | $3.78 | $4.16 |
| Indicator | DARE | MDBH |
|---|---|---|
| Relative Strength Index (RSI) | 37.58 | 37.43 |
| Support Level | $0.63 | N/A |
| Resistance Level | $0.88 | $3.17 |
| Average True Range (ATR) | 0.04 | 0.11 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 40.10 | 52.70 |
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The company operates in two reportable segments: a broker dealer & intellectual property service; and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.